Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study
ConditionGlioblastoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Paul Strauss
About this trial
ReciDOPA is a phase II, single-stage randomized, multicenter, prospective trial assessing the efficacy of an irradiation protocol based on Intensity-modulated radiation therapy with simultaneous-integrated boost guided by FDOPA-PET in patient with recurrent glioblastoma.
Eligibility criteria
Qualifiers
Age > 18 years
Glioblastoma, World Health Organization (WHO) grade IV, histologically proven
Performance status 0, 1 or 2
Neurological status ≥ 2
Disqualifiers
Patient with contraindication to MRI or PET
Glioblastomatose
Pregnancy or breastfeeding
Patient that do not understand French
Trial design
Treatments tested in this trial
- Simultaneous-integrated boost with IMRT
Treatment groups
54 Participants
are divided into 2 treatment groupsSponsors and collaborators
Centre Paul Strauss
Lead sponsor
Centre Georges François Leclerc
Collaborator
Source ClinicalTrials.gov